What do recent trials tell us about statins?

Research output: Contribution to journalArticlepeer-review


Recent large-scale, randomized, placebo-controlled trials in primary and secondary prevention of GHD have shown an overwhelming benefit for lipid-lowering therapy. These trials, which used HMG-CoA reductase inhibitors, showed reductions in cardiac events, cardiac mortality, and overall mortality. These benefits are achieved with no significant increase in adverse events and no increase in cancer deaths. Now that scientific studies have been conducted and the data have established the benefits of treatment in patients with coronary heart disease and risk factors, the challenge to the medical community is to apply this knowledge by implementing appropriate cholesterol-lowering treatment when indicated.

Original languageEnglish
Pages (from-to)S67-S69
JournalAmerican Journal of Managed Care
Issue numberMAR
StatePublished - Dec 1 1997


Dive into the research topics of 'What do recent trials tell us about statins?'. Together they form a unique fingerprint.

Cite this